About RAINMED-B Company

We were founded in 2014 and are committed to becoming the world's leading vascular intervention robot company. Currently, we focus on the design, development and commercialization of a coronary angiography-based blood flow reserve fraction system (“CaFR system”) and a coronary angiography based microvascular resistance index system (“caIMR system”). Our core products (CaffR system and CaIMR system) are innovative medical devices for evaluating the severity of myocardial ischemia due to coronary artery stenosis and microvascular dysfunction (CAD-related causes). It is designed to replace the use of pressure guides, greatly reduce technical errors and operation time, thereby improving physiological assessment. Both systems are currently used separately for accurate CAD diagnostics. Since FFR measures macrocirculation in arteries (accounting for 5% of all arteries), and IMR measures microcirculation in arteries (accounting for 95% of all arteries), the combined use of IMR and FFR can provide a comprehensive assessment of coronary blood circulation in CAD patients. These two systems are expected to become the core and key modules for our future vascular interventional surgery robots. Our CaffR system has obtained both European CE certification and National Drug Administration approval. It was also successfully registered in the Commonwealth of Australia (“Australia”) in 2022 and approved by the Government Drug Administration (“TGA”). Our CaffR system has a high accuracy rate of over 95% and a convenient operation process that takes less than five minutes. It has become a leading domestic FFR measurement product, and is fiercely competing with leading international medical device companies for the leading position in the domestic FFR measurement market. We plan to further cover patients with acute STEMI, acute nSTEMI, and HFpEF from the current scope (i.e., patients with stable angina pectoris, unstable angina pectoris, and patients after the acute phase of myocardial infarction). Furthermore, our caIMR system was approved by the National Drug Administration in April 2023. The system is the only minimally invasive IMR measurement product in the world that has completed confirmatory clinical trials, and is the world's first minimally invasive IMR system approved for commercialization. In December 2022, our CaffR system and CaIMR system were included in the “China Expert Consensus on Computational Coronary Physiology Testing Technology” (“Expert Consensus”). The expert consensus filled the gap where the clinical application of computational physiological indicators in interventional treatment of coronary heart disease in China lacked guidelines and provided a basis for its standardized application and expansion of the scope of application. Based on our CaffR system and CaIMR system, and in combination with the Group's other related products, we plan to launch our vascular interventional surgical robot, which is a one-stop hybrid program that automates the entire PCI process by connecting and integrating all fields of clinical application for diagnosis and treatment. In March 2023, the Group acquired 68.32% of the shares of Tianjin Yuehekang Biotechnology Co., Ltd. (“Tianjin Yuekang”), and Tianjin Yuehekang became an indirect subsidiary of the company. Its main business is in the field of biochemical in vitro diagnostic reagents, and is a diversified high-tech enterprise integrating R&D, production and sales of group external diagnostic products. It has now obtained 85 Class II registration certificates for biochemical diagnostic reagent products and corresponding production licenses, covering major diagnostic categories such as liver function, kidney function, lipids and cardiomyology. The products cover a wide range of diagnostic categories such as liver function, kidney function, lipids and cardiomyology. blood” and Vascular IVD innovates a series of accurate diagnostic products such as “and peptides”. The Group's accurate diagnosis product line will expand from “covering the entire surgical process” to “immediate examination upon admission” and “immediate bedside examination”, further improving the Group's product layout. Our vision Adhering to the purpose of “shaping precision medicine and serving the health of all”, we will rely on technical accumulation in medical imaging algorithms, hydrodynamic analysis, high-performance mechanical design, and high-end interventional consumables research and development capabilities to launch interventional surgical robots, and gradually build unmanned operating rooms to enhance the clinical value of products and create a new situation of precision medicine in the field of interventional intervention.